REFERENCES

- 1. Brazin, S. A., Simkovich, J. W. & Johnson, W. T.: Herpes zoster during pregnancy. Obstet Gynecol 53 (2): 175-181, 1979.
- David, T. J. & Williams, M. L.: Herpes zoster in infancy. Scand J Infect Dis 11: 185-186, 1979.
- DeNicola, L. K. & Hanshaw, J. B.: Congenital and neonatal varicella. J Pediatr 94: 175–176, 1979.
- Dworsky, M., Whitley, R. & Alford, C.: Herpes zoster in early infancy. Am J Dis Child 134: 618– 619, 1980.
- Gershon, A. A.: Varicella in mother and infant: problems old and new. In Infections of the Fetus and Newborn. Progress in Clinical and Biological Research (ed. S. Krugman & A. A. Gershon), vol. 3, pp. 79–95. Alan R. Liss. New York, 1975.
- Hanshaw, J. B. & Dudgeon, J. A.: Viral diseases of the fetus and newborn. Introduction. *In* Major Problems in Clinical Pediatrics, vol. 17. pp. 1–9.
 W. B. Saunders Company, Philadelphia, 1978.
- Hope-Simpson, R. E.: The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 58: 9-20, 1965.
- Kouvalainen, K., Salmi, A. & Salmi, T. T.: Infantile herpes zoster. Scand J Infect Dis 4: 91-96, 1972.
- Laude, T. A. & Rajkumar, S.: Herpes zoster in a 4-month-old infant. Arch Dermatol 116: 160, 1980.
- Taranger, J., Blomberg, J. & Strannegård, Ö.: Intrauterine varicella: a report of two cases associated with hyper-A-immunoglobulinemia. Scand J Infect Dis 13: 297-300, 1981.

Keratodermia punctata hereditaria Treated with Etretinate (Tigason)

Jørgen V. Christiansen

Department of Dermatology, Marselisborg Hospital, University of Aarhus, Aarhus, Denmark

Received August 10, 1982

Abstract. Nine patients with keratodermia punctata hereditaria were treated with etretinate 0.5 mg/l mg/kg/day for 3 to 13 months. The result was good to moderate in 7 of the 9 patients.

Key words: Keratodermia punctata hereditaria; Etretinate (Tigason)

Bergfeld et al. (1) treated 6 patients with keratosis palmaris et plantaris with isotretinoin, with good results in 5 of 9 patients after 8 to 12 weeks observation period. We have treated 9 patients with keratodermia punctata hereditaria with etretinate (Tigason).

MATERIAL AND METHODS

Nine patients, 4 men and 5 women, were treated for 3 to 39 months with etretinate 0.5 mg/1 mg/kg/day. The mean age of the group was 57 years. Measurements of safety and efficacy were made at monthly intervals.

RESULTS

The results were good in 3 patients, moderate in 4, and there was no effect in 2 patients. The treatment was stopped in 6 of 9 patients after 3 to 13 months. One man and 2 women had continued treatment up to 39 months.

Side effects

All the patients had some dryness of the mucous membranes, one man and 2 women had some defluvium and one man and one woman had some pruritus. There was no increase in liver transaminases during the treatment.

DISCUSSION

The treatment of all types of hereditary keratodermia has been unrewarding in the past. We now seem to have some prospect of helping these patients. There seems to be almost the same positive outcome with etretinate as found with isotretinoin. In most cases the treatment had to be continued for a rather long time, but patients seem to tolerate the treatment rather well.

REFERENCE

 Bergfeld, W. F., Derbes, V. J., Elias, P. M., Frost, P., Greer, K. E. & Shupack J. L.: The treatment of keratosis palmaris et plantaris with isotretinoin. Am Acad Dermatol 6: 727, 1982.

Ear Ache during Etretinate Treatment

Lennart Juhlin

Department of Dermatology, University Hospital, Uppsala, Sweden

Received August 2, 1982

Abstract. Two patients with ear ache related to etretinate treatment in a dose of 50-75 mg are reported. The ache disappeared within a week after lowering the dose and reappeared when the dose was increased.

Key words: Etretinate; Ear ache; Side effects